(S1 (S (S (NP (NN Licochalcone) (NN A)) (ADVP (RB significantly)) (VP (VBZ suppresses) (NP (NN LPS) (NN signaling) (NN pathway)) (PP (IN through) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN NF-kappaB) (NN p65) (NN phosphorylation))) (PP (IN at) (NP (NN serine) (CD 276))))))) (. .)))
(S1 (S (S (NP (NP (NN Licorice) (NN root)) (, ,) (NP (NN Glycyrrhiza) (NN inflata)) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (JJ traditional) (NN medicine)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ bronchial) (NN asthma)) (CC and) (NP (NN inflammation)))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (PRP$ its) (JJ anti-inflammatory) (NN activity)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN clarified))))) (. .)))
(S1 (S (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN Licochalcone) (NN A)) (, ,) (NP (NP (DT a) (JJ major) (NN component)) (PP (IN of) (NP (NNP G.) (NN inflata)))) (, ,))) (PP (IN on) (NP (DT the) (NN LPS) (NN signaling) (NN pathway)))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NN Licochalcone) (NN A)) (ADVP (RB remarkably)) (VP (VBD inhibited) (NP (NP (JJ LPS-induced) (NN NO) (NN production)) (, ,) (CC and) (NP (NP (NP (NN TNFalpha) (NN expression)) (CC and) (NP (NN MCP-1) (NN expression))) (PP (IN in) (NP (CC both) (NP (NN RAW264.7) (NNS cells)) (CC and) (NP (JJ primary) (NNS macrophages))))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN injected) (PP (IN with) (NP (NP (NN Licochalcone) (NN A)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN injection)) (PP (IN of) (NP (NN LPS))))))))))) (, ,) (NP (NP (DT the) (NN serum) (NN level)) (PP (IN of) (NP (NP (NN TNFalpha)) (CC and) (NP (NN MCP-1)))) (PP (IN in) (NP (NN C57BL/6) (NNS mice)))) (VP (VBD was) (ADVP (RB clearly)) (VP (VBN decreased) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NN Licochalcone) (NN A)) (VP (VBZ has) (NP (DT a) (JJ potent) (JJ anti-inflammatory) (NN effect)) (ADVP (CC both) (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo))))))))))) (. .)))
(S1 (S (S (ADVP (RB Strikingly)) (, ,) (NP (NN Licochalcone) (NN A)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (JJ LPS-induced) (NN NF-kappaB) (JJ transcriptional) (NN activation)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (PRP it)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (CONJP (RB not) (RB only)) (NP (NP (DT the) (NP (NN phosphorylation)) (CC and) (NP (NN degradation))) (PP (IN of) (NP (NN IkappaBalpha)))) (CONJP (CC but) (RB also)) (NP (JJ nuclear) (NN translocation)) (CC and) (NP (NN DNA) (NN binding) (NN activity))) (PP (IN of) (NP (NN NF-kappaB) (NN p65))))))) (. .)))
(S1 (S (S (ADVP (RB Interestingly)) (, ,) (NP (NN Licochalcone) (NN A)) (ADVP (RB markedly)) (VP (VBD inhibited) (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NN p65))) (PP (IN at) (NP (NN serine) (CD 276)))))) (. .)))
(S1 (S (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (PRP it)) (VP (VBD reduced) (NP (NN NF-kappaB) (NN transactivation)) (PP (IN by) (S (VP (VBG preventing) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN p65))) (PP (IN with) (NP (NN p300))))))))) (. .)))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NN Licochalcone) (NN A)) (VP (MD might) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (JJ potent) (JJ anti-inflammatory) (NN effect)) (PP (IN of) (NP (NNP G.) (NN inflata))))) (PP (IN through) (NP (NP (DT the) (JJ unique) (NN mechanism)) (PP (IN of) (NP (NN NF-kappaB) (NN inhibition)))))))) (. .)))
